spacer
home > ebr > summer 2002 > contract development - industry spend and value
PUBLICATIONS
European Biopharmaceutical Review

Contract Development - Industry Spend and Value

We have entered a period of growth in the drug development industry, driven largely by financial investment and an increase in validated targets. This expansion has created a competitive need for finite drug development resources. As an employee of a preclinical testing company, I will be drawing on my experiences to comment on the value of the contract research organisation (CRO) and the growth of contract research, explaining these in the context of the biopharmaceutical industry.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Benjamin Jones, Business Development Manager at Huntingdon Life Sciences Ltd
Dr Benjamin Jones has a bachelor's degree in Zoology from Nottingham University, and received his PhD from the Welsh School of Pharmacy at Cardiff University.
After a short academic career he joined Huntingdon Life Sciences (HLS) Business Development Group in early 2000. Ben has worked for Huntingdon in the US and the UK and is currently responsible for biopharmaceutical and inhalation toxicology business development.

spacer
Dr Benjamin Jones
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Organization Updates

Philadelphia, PA – May 20, 2019 – PCI Pharma Services, a leading biopharmaceutical outsourcing services provider, is pleased to announce the following management updates to help drive the company’s future vision, strategy and growth.
More info >>

White Papers

Unmet Medical Needs? Impacted by unmet Life Sciences Staffing Needs?

Clinical Professionals

Whilst the majority of Clinical Professionals clients are working to discover and develop innovative, cost effective medicines that address unmet medical needs they are not impacting the unmet needs of training and developing new recruits into the pharma industry. The impact is highlighted within entry level Clinical Trial Administrators and Clinical Research Associates (CTA/CRA). In the past the Pharmaceutical industry had highly developed training programs for these sought after candidates. As the use of outsourcing models and CRO’s has increased and fewer Pharma businesses embark on their own R&D a substantial gap is developing in newly trained Life Science graduates entering the market to commence a career within R&D. As further financial cuts are made within R&D spend this already dire situation continues to escalate.
More info >>

 
Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement